

Drug Policy:

Zynlonta™ (loncastuzimab tesirine-lpyl)

POLICY NUMBER UM ONC_1434	SUBJECT Zynlonta™ (loncastuzimab tesirine-lpyl)	DEPT/PROGRAM UM Dept	PAGE 1 OF 3
DATES COMMITTEE REVIEWED 06/09/21, 11/15/21, 05/11/22, 06/08/22, 07/13/22, 06/14/23, 06/12/24	APPROVAL DATE June 12, 2024	EFFECTIVE DATE June 28, 2024	COMMITTEE APPROVAL DATES 06/09/21, 11/15/21, 05/11/22, 06/08/22, 07/13/22, 06/14/23, 06/12/24
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee	
NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS	APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Zynlonta (loncastuzimab tesirine-lpyl) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

B. Diffuse Large B-Cell Lymphoma (DLBCL)

1. Zynlonta (loncastuzimab tesirine-lpyl) may be used as monotherapy in members with CD19 + relapsed/refractory Diffuse Large B-Cell Lymphoma (CD-19 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry) **AND** as follows:
 - a. The member has relapsed or refractory diffuse large B-cell lymphoma-NOS (DLBCL not otherwise specified), DLBCL arising from low-grade lymphoma, or high-grade B-cell lymphoma **AND**

- b. The member has had disease progression on two or more lines of systemic therapies (e.g., R- CHOP, R-ICE, R-DHAP, R-ESHAP, R-EPOCH, or R-GDP).

III. EXCLUSION CRITERIA

- A. Zynlonta (loncastuzimab tesirine-lpyl) is being used on or after disease progression with the same regimen.
- B. Lack of confirmed documentation for CD-19 tumor expression by any standard test.
- C. Dosing exceeds single dose limit of Zynlonta (loncastuzimab tesirine-lpyl) 0.15 mg/kg (the first 2 cycles); 0.075 mg/kg (cycle 3 and beyond).
- D. Investigational use of Zynlonta (loncastuzimab tesirine-lpyl) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - 4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - 7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES



EmblemHealth®

ConnectiCare

Evolut Utilization Management Oncology Policy 1434 for Zynlonta (loncastuzimab tesirine-lpyl)

© 2023 Evolut Health LLC All Rights Reserved

- A. Caimi PF, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790-800.
- B. Zynlonta prescribing information. ADC Therapeutics America, Murray Hill, New Jersey 2023.
- C. Clinical Pharmacology Elsevier Gold Standard 2023.
- D. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2023.
- E. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.
- F. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2023.
- G. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.
- H. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services:
<https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.